IQVIA’s Orchestrated Customer Engagement (OCE) Solution Selected by 140 Life Sciences Companies in Nearly 90 Countries
- S&P 500, Dow climb for third day and close at records
- Tesla (TSLA) China Numbers 'Robust' - Wedbush
- Apple (AAPL) Shares Seen as 'Attractive' as Recent Checks Show Continuously Strong Demand - Citi
- Investors Poured More Money Into Stocks in Past 5 Months Than Last 12 Years, Says BofA, Analysts Worried About Stretched Valuations
- Amazon.com warehouse workers vote to reject forming union in Alabama
Get instant alerts when news breaks on your stocks. Claim your 1-week free trial to StreetInsider Premium here.
IQVIA OCE sees rapid growth, including expanded global OCE rollout by a top-10 pharma company
DANBURY, Conn. & RESEARCH TRIANGLE PARK, N.C--(BUSINESS WIRE)-- IQVIA™ (NYSE: IQV) today announced that 140 life science companies in nearly 90 countries have selected Orchestrated Customer Engagement (OCE) as their customer engagement solution. This milestone reflects the growing demand within the market for IQVIA’s commercial technology to meet the evolving needs of life science companies.
Most recently, Laboratoires Théa, a leading independent eye care group in Europe, has joined the growing list of clients and is leveraging OCE to accelerate its global digital transformation, creating more impactful customer interactions. Demand for OCE remained strong in 2020, with 60 additional customers deploying the OCE platform. OCE customers include several top-20 global pharmaceutical companies such as AstraZeneca, Novo Nordisk and Roche, as well as Adhera Therapeutics, Napo Pharmaceuticals, Pierre Fabre Pharmaceuticals, PruGen Pharmaceuticals, Recordati, Theramex and Zentiva as well as the global expansion of OCE with a top-15 pharma company.
“We recognized early on that existing customer engagement solutions weren’t addressing the evolving needs of life sciences clients,“ said Kevin Knightly, president, Technology & Commercial Solutions, IQVIA. “The environment in which our customers operate is complex, requiring engagement with multiple healthcare stakeholders across multiple channels. OCE is a transformative technology platform helping connect different customer-facing functions and harmonizing multichannel interactions to improve commercial performance and customer trust and loyalty.”
OCE not only connects enterprises with their customers, but it also connects departments within an enterprise, breaking down organizational silos. Artificial intelligence can analyze interactions and outcomes to enhance productivity by making recommendations for commercial activities. The result is seamless orchestration of all customer-facing personal and digital touchpoints, creating an exceptional, personalized experience.
IQVIA (NYSE: IQV) is a leading global provider of advanced analytics, technology solutions, and clinical research services to the life sciences industry. IQVIA creates intelligent connections across all aspects of healthcare through its analytics, transformative technology, big data resources and extensive domain expertise. IQVIA Connected Intelligence™ delivers powerful insights with speed and agility — enabling customers to accelerate the clinical development and commercialization of innovative medical treatments that improve healthcare outcomes for patients. With approximately 68,000 employees, IQVIA conducts operations in more than 100 countries.
IQVIA is a global leader in protecting individual patient privacy. The company uses a wide variety of privacy-enhancing technologies and safeguards to protect individual privacy while generating and analyzing information on a scale that helps healthcare stakeholders identify disease patterns and correlate with the precise treatment path and therapy needed for better outcomes. IQVIA’s insights and execution capabilities help biotech, medical device and pharmaceutical companies, medical researchers, government agencies, payers and other healthcare stakeholders tap into a deeper understanding of diseases, human behaviors and scientific advances, in an effort to advance their path toward cures. To learn more, visit www.iqvia.com.
Tor Constantino, IQVIA Media Relations (firstname.lastname@example.org)
Andrew Markwick, IQVIA Investor Relations (email@example.com)
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- AHF Welcomes Biden’s Proposed 15% HUD Budget Increase
- Theratechnologies Presents New In Vivo Pre-Clinical Data at AACR Demonstrating Significant Anti-Tumor Activity of TH1902 in All Studied Cancer Types
- Positive Findings From Phase 1b Trial of GlycoMimetics’ GMI-1359 To Be Presented at AACR 2021 Meeting
Create E-mail Alert Related CategoriesBusiness Wire, Press Releases
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!